<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03917199</url>
  </required_header>
  <id_info>
    <org_study_id>2015/19/B/NZ5/03502</org_study_id>
    <nct_id>NCT03917199</nct_id>
  </id_info>
  <brief_title>Utility of Regadenoson Low-dose Dynamic Computed Tomography for Myocardial Perfusion Assesment (ULYSSES Study).</brief_title>
  <acronym>ULYSSES</acronym>
  <official_title>Utility of Regadenoson Low-dose Dynamic Computed Tomography for Myocardial Perfusion Assesment (ULYSSES Study).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Cardiology, Warsaw, Poland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Science Centre, Poland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Cardiology, Warsaw, Poland</source>
  <brief_summary>
    <textblock>
      The ULYSSES study is a single-center, prospective study aimed at evaluation of myocardial
      ischemia using regadenoson low-dose dynamic computed tomography myocardial perfusion imaging
      (CTP) in patients diagnosed with intermediate coronary artery stenoses in referrence to the
      magnetic resonance myocardial perfusion imaging (MR MPI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ULYSSES study is a single-center, prospective study aimed at evaluation of myocardial
      ischemia using regadenoson low-dose dynamic computed tomography myocardial perfusion (CTP) in
      patients diagnosed with intermediate coronary artery stenoses in referrence to the magnetic
      resonance myocardial perfusion imaging (MR MPI).

      The main objectives of the study are:

        -  to evaluate feasibility of low - dose regadenoson dynamic computed tomography myocardial
           imaging protocol

        -  to assess the diagnostic value of quantitative dynamic CTP based absolute parameters
           (myocardial blood flow - MBF, myocardial blood volume - MBV, perfused capillary blood
           volume - PCBV, peak value - PV, time to peak - TTP) in reference to magnetic resonance
           myocardial perfusion imaging

        -  to assess the diagnostic value of quantitative dynamic CTP based relative parameters
           (relative myocardial blood flow - MBFR, relative myocardial blood volume - MBVR,
           relative perfused capillary blood volume - PCBVR, relative peak value - PVR, relative
           time to peak - TTPR) in reference to magnetic resonance myocardial perfusion imaging

        -  evaluation of safety of regadenoson low-dose dynamic CTP.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Actual">July 11, 2019</completion_date>
  <primary_completion_date type="Actual">July 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of feasibility of regadenoson low - dose dynamic computed tomography perfusion protocol.</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluation of the quality of CTP images asessed by experienced readers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of ischemia in regadenoson low-dose dynamic CTP in reference to magnetic resonance myocardial perfusion imaging (MR MPI).</measure>
    <time_frame>24 months</time_frame>
    <description>The presence of ischemia in CTP per myocardial segment.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Evaluation of radiation dose during regadenoson low-dose dynamic CTP.</measure>
    <time_frame>24 months</time_frame>
    <description>Assessment of DLP (dose lenght product).</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of contrast agent dose during regadenoson low-dose dynamic CTP.</measure>
    <time_frame>24 months</time_frame>
    <description>Assessment of contast agent dose (ml).</description>
  </other_outcome>
  <enrollment type="Actual">60</enrollment>
  <condition>Myocardial Perfusion Imaging</condition>
  <condition>Computed Tomography</condition>
  <condition>Coronary Artery Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Study population as described in inclusion and exclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age over 18 years

          -  signing written, informed consent by the patient for participation in the study

          -  patients who are asymptomatic or with symptoms of stable coronary heart disease

          -  intermediate coronary artery stenosis of at least one coronary artery in CTCA

        Exclusion Criteria:

          -  the symptoms of unstable ischemic heart disease and /or myocardial infarction,

          -  the history of myocardial infarction

          -  patients with impaired renal function (GFR &lt;60 mL)

          -  contraindications for computed tomography or magnetic resonance imaging (including
             pregnancy, the presence of a cardiac pacemaker or cardioverter-defibrillator,
             claustrophobia, the presence of metal elements, etc.);

          -  contraindications to the administration of iodine contrast media (including allergy to
             contrast, unstable hyperthyroidism, etc.)

          -  contraindications to administration of regadenosone (hypersensitivity to the active
             substance, second or third degree atrioventricular block or other sinus node
             dysfunction, unstable angina, hypotension, decompensated heart failure, etc.);

          -  heart failure with impaired left ventricular systolic function

          -  a significant valvular heart disease

          -  presence of aortic aneurysm or aortic dissection

          -  persistent atrial fibrillation / atrial flutter

          -  hypertrophic cardiomyopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cezary Kepka, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Cardiology, warsaw, PL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Cardiology</name>
      <address>
        <city>Warsaw</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 2, 2017</study_first_submitted>
  <study_first_submitted_qc>April 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>September 16, 2019</last_update_submitted>
  <last_update_submitted_qc>September 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myocardial perfusion imaging</keyword>
  <keyword>computed tomography perfusion</keyword>
  <keyword>regadenoson</keyword>
  <keyword>dynamic perfusion</keyword>
  <keyword>coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

